Human IL-2 mutein with higher antitumor efficacy than wild type IL-2

Journal of Immunology

Volumn 190, Issue 12, 2013, Pages 6230-6238

  Carmenate, Tania ^a   Pacios, Anabel ^a   Enamorado, Michel ^a   Moreno, Ernesto ^a   Garcia Martínez, Karina ^a   Fuente, Dasha ^b   León, Kalet ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b Biomodels Unit   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MUTANT PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE EFFECTIVENESS; COMPUTER MODEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; EFFECTOR CELL; FEMALE; IN VITRO STUDY; LIVER TOXICITY; LUNG CARCINOMA; LUNG METASTASIS; LUNG TOXICITY; MATHEMATICAL MODEL; METASTASIS INHIBITION; METASTATIC MELANOMA; MOLECULAR INTERACTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TOXICITY TESTING; WILD TYPE;

ANIMALS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, THEORETICAL; MUTATION; NEOPLASMS, EXPERIMENTAL; PROTEIN STRUCTURE, QUATERNARY;

EID: 84879091213     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201895     Document Type: Article

References (30)

1. Kovanen, P. E., and W. J. Leonard. 2004. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol. Rev. 202: 67-83. (Pubitemid 39576905)
2. Lin, J. X., and W. J. Leonard. 1997. Signaling from the IL-2 receptor to the nucleus. Cytokine Growth Factor Rev. 8: 313-332.
3. Morgan, D. A., F. W. Ruscetti, and R. Gallo. 1976. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007-1008.
4. Smith, K. A. 1988. Interleukin-2: inception, impact, and implications. Science 240: 1169-1176.
5. Rosenberg, S. A. 2001. Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. 250: 462-475. (Pubitemid 34013510)
6. Siegel, J. P., and R. K. Puri. 1991. Interleukin-2 toxicity. J. Clin. Oncol. 9: 694-704.
7. Boyman, O., and J. Sprent. 2012. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12: 180-190.
8. Liao, W., J. X. Lin, L. Wang, P. Li, and W. J. Leonard. 2011. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat. Immunol. 12: 551-559.
9. Kündig, T. M., H. Schorle, M. F. Bachmann, H. Hengartner, R. M. Zinkernagel, and I. Horak. 1993. Immune responses in interleukin-2-deficient mice. Science 262: 1059-1061. (Pubitemid 24035046)
10. Sadlack, B., H. Merz, H. Schorle, A. Schimpl, A. C. Feller, and I. Horak. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261. (Pubitemid 23320289)
11. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164.
12. Malek, T. R. 2003. The main function of IL-2 is to promote the development of T regulatory cells. J. Leukoc. Biol. 74: 961-965. (Pubitemid 38040316)
13. Cesana, G. C., G. DeRaffele, S. Cohen, D. Moroziewicz, J. Mitcham, J. Stoutenburg, K. Cheung, C. Hesdorffer, S. Kim-Schulze, and H. L. Kaufman. 2006. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24: 1169-1177. (Pubitemid 46638815)
14. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949. (Pubitemid 39273735)
15. Shanafelt, A. B., Y. Lin, M. C. Shanafelt, C. P. Forte, N. Dubois-Stringfellow, C. Carter, J. A. Gibbons, S. L. Cheng, K. A. Delaria, R. Fleischer, et al. 2000. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat. Biotechnol. 18: 1197-1202.
16. Rao, B. M., A. T. Girvin, T. Ciardelli, D. A. Lauffenburger, and K. D. Wittrup. 2003. Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity. Protein Eng. 16: 1081-1087. (Pubitemid 38281759)
17. García-Marínez, K., and K. León. 2012. Modeling the role of IL2 in the interplay between CD41 helper and regulatory T cells: studying the impact of IL2 modulation therapies. Int. Immunol. 24: 427-446.
18. Wang, A., S. D. Lu, and D. F. Mark. 1984. Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science 224: 1431-1433. (Pubitemid 14123340)
19. Moya, G., L. J. González, V. Huerta, Y. Garća, V. Morera, D. Pérez, F. Breña, and M. Araña. 2002. Isolation and characterization of modified species of a mutated (Cys125 -Ala) recombinant human interleukin-2. J. Chromatogr. A 971: 129-142. (Pubitemid 35247674)
20. Smith, K. A. 2006. The quantal theory of immunity. Cell Res. 16: 11-19. (Pubitemid 43129304)
21. Gillis, S., M. M. Ferm, W. Ou, and K. A. Smith. 1978. T cell growth factor: parameters of production and a quantitative microassay for activity. J. Immunol. 120: 2027-2032. (Pubitemid 8356952)
22. Donohue, J. H., M. T. Lotze, R. J. Robb, M. Rosenstein, R. M. Braziel, E. S. Jaffe, and S. A. Rosenberg. 1984. In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Res. 44: 1380-1386. (Pubitemid 14174450)
23. Harvill, E. T., J. M. Fleming, and S. L. Morrison. 1996. In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J. Immunol. 157: 3165-3170. (Pubitemid 126450079)
24. Wang, X., M. Rickert, and K. C. Garcia. 2005. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 310: 1159-1163. (Pubitemid 41681737)
25. Heaton, K. M., G. Ju, and E. A. Grimm. 1993. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. Cancer Res. 53: 2597-2602. (Pubitemid 23168029)
26. Heaton, K. M., G. Ju, and E. A. Grimm. 1994. Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs. Ann. Surg. Oncol. 1: 198-203.
27. Krieg, C., S. Létourneau, G. Pantaleo, and O. Boyman. 2010. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl. Acad. Sci. USA 107: 11906-11911.
28. Boyman, O., M. Kovar, M. P. Rubinstein, C. D. Surh, and J. Sprent. 2006. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311: 1924-1927.
29. Létourneau, S., E. M. van Leeuwen, C. Krieg, C. Martin, G. Pantaleo, J. Sprent, C. D. Surh, and O. Boyman. 2010. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc. Natl. Acad. Sci. USA 107: 2171-2176.
30. Rojas, G., A. Pupo, K. Leon, J. Avellanet, T. Carmenate, and S. Sidhu. 2013. Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: a versatile platform for fine epitope mapping. Immunobiology 218: 105-113.